Emergex Vaccines expands at Milton Park

The current COVID-19 pandemic has put vaccines in the spotlight like never before

Emergex Vaccines, which focuses on the development of synthetic T-cell vaccines against global infectious disease threats such as COVID-19, Dengue fever, Zika, Ebola and pandemic Flu, has expanded at Oxfordshire’s Milton Park.

Emergex’s vaccines are designed to prime recipients’ immune systems to recognise infections, much like a natural infection would, to protect people from disease. Their vaccines are 100% synthetic – requiring no biology for manufacturing – and therefore have the potential to be rapidly produced and cost-effectively scaled. They are delivered through a microneedle system which allows for convenient administration through a patch and require no cold chain in storage or distribution.

Emergex employs around 30 people, and as part of the recent expansion, the company has taken on almost 3,000 sq ft of new space on the park, which is in addition to Emergex’s R&D facility at 65 Innovation Drive.

Storme Moore-Thornicroft, Emergex’s co-founder and COO commented: “The current COVID-19 pandemic has put vaccines in the spotlight like never before. We believe that our vaccine technology can play a critical role in creating safe, effective vaccines that can be rapidly and widely deployed against some of the most pressing disease threats in the world. Our expansion at Milton Park, at the heart of the Oxfordshire sciences ecosystem, reflects our continued growth, and we look forward to working in these facilities to further advance our pipeline.”

Philip Campbell, MEPC commercial director at Milton Park said: “Emergex Vaccines needed expansion space, and we were pleased to accommodate their growth plans. The work the team is doing to address serious infectious diseases across the world through its highly innovative vaccine technology is impressive.”

Recent news

Times Higher Education article – female academic founders

Times Higher Education article – female academic founders

Advanced Oxford member and collaborator considers the role of investors in supporting female academic founders Simonetta Manfredi is a professor of equality and diversity management, and the Director for Research, Innovation and Enterprise at Oxford Brookes...

read more
Amano Enzyme establishes new European hub at Milton Park

Amano Enzyme establishes new European hub at Milton Park

The world’s leading manufacturer of speciality enzymes, has established its new Europe, Middle East and Africa (EMEA) hub at Milton Park. Amano Enzymes, the Japanese biotechnology company - which uses its enzymes to boost the flavour, texture, colour, digestion and...

read more
Next step in expansion of The Oxford Science Park

Next step in expansion of The Oxford Science Park

Detailed planning application submitted for Plot 27 New R&D building part of >500,000 sq ft expansion plan as the Park innovation ecosystem grows. The Oxford Science Park (TOSP), one of Europe’s leading locations for science and technology companies, is...

read more
Loading...